Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Trading Plan

Castle Biosciences CEO, Derek J. Maetzold, executed multiple sales of company stock through various trusts under a pre-arranged 10b5-1 trading plan.

Summary

• Derek J. Maetzold, CEO of Castle Biosciences, sold shares of the company's common stock on January 6th and 7th, 2025.
• The sales were executed through multiple trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several 2018 Remainder Trusts for his children.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• The sales occurred at varying prices, with weighted average prices of $28.421, $29.131, $30.175, and $30.139 per share.
• A total of 122,866 shares are held by DJM Grantor Retained Annuity Trust No. 5 and 26,134 shares are held by DJM Grantor Retained Annuity Trust No. 6.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither particularly positive nor negative. The sales are not unexpected and do not indicate a change in the company's fundamentals.

Risks

• The sales by the CEO, even under a pre-arranged plan, could be perceived negatively by some investors.
• The market may react to the reduction in the CEO's direct and indirect holdings.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice for executives to manage their stock sales while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Castle Biosciences.
• Companies such as Exact Sciences (EXAS) and Myriad Genetics (MYGN) also see similar filings from their executives, indicating that this type of activity is not unusual.
• The volume of shares sold is not unusual for a CEO of a company of this size, and the prices are within the normal trading range for the stock.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sales, although the pre-arranged nature of the transactions should mitigate any negative impact.
• Employees may be aware of the CEO's stock sales, but the use of a 10b5-1 plan should reassure them that the transactions are not based on any non-public information.

Key Dates

Keywords

insider trading, Form 4, stock sale, Rule 10b5-1, Castle Biosciences, CSTL, Derek Maetzold, executive stock